News Lilly chases Amgen with migraine drug filing Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
News Allergy Tx plots grass pollen jab launch after German okay Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
